Zhao Yi Wang

Founder at Beijing Shenogen Pharma Group Ltd.

65 year

Health Technology

Consumer Services

Profile

Zhao Yi Wang is the founder of Shenogen Pharma Group Ltd.
and Beijing Shenogen Pharma Group Ltd., both founded in 2006.
He holds the title of Director & Chief Science Officer at Shenogen Pharma Group Ltd.
and Director, Chief Scientific Officer & Deputy GM at Beijing Shenogen Pharma Group Ltd.
Dr. Wang received a doctorate degree from the University of Washington in 1994.

Zhao Yi Wang active positions

Companies	Position	Start
Beijing Shenogen Pharma Group Ltd. Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.	Founder	2005-12-31
Beijing Shenogen Pharma Group Ltd. Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.	Founder	2005-12-31

All active positions of Zhao Yi Wang

Training of Zhao Yi Wang

University of Washington

Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Zhao Yi Wang's experience

Connections

100 +

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	1
Beijing Shenogen Pharma Group Ltd. Beijing Shenogen Pharma Group Ltd. Pharmaceuticals: MajorHealth Technology Beijing Shenogen Pharma Group Co. Ltd. engages in the manufacture of icaritin drug products. It focuses on the treatment of multiple malignant tumors such as hepatocellular carcinoma, breast cancer, non-small cell lung cancer, and lymphoma. The company was founded by Kun Meng and Zhao Yi Wang on May 5, 2008 and is headquartered in Beijing, China.	Health Technology